Technology | Balloon Catheter | August 23, 2018

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval

New balloon, also approved in Europe and Japan, addresses EVAR stent graft seal and temporary vessel occlusion challenges

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval

August 23, 2018 — W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore Molding & Occlusion Balloon. The compliant polyurethane balloon catheter is designed to assist in the expansion of self-expanding stent grafts or to temporarily occlude large-diameter vessels. The device also received approval from the Japanese Ministry of Health, Labour and Welfare, and receipt of CE Mark. It meets all endovascular aortic repair (EVAR) procedural requirements, according to Gore – a single balloon that replaces the need for multiple molding and occlusion balloons.

The device’s radial expansion force across the range of EVAR device sizes enables physicians to consistently seat and seal grafts with confidence. This more efficient graft seal may reduce procedural time and the risk of Type 1 endoleaks. The device is also engineered with the lowest profile to reduce the potential of access-related complications, and its pushability and trackability offers enhanced control with uncompromised inflation and deflation time, according to Gore.

The new device is supplied in a single catheter length of 90 cm. This will enable use with current Gore Excluder Devices as well as future Gore devices while still being compatible with a 180 cm length guidewire.

Besides adding value through consistently reliable technical success and patient experience, the use of a single balloon allows for efficiency and inventory optimization. Use of a single molding and occlusion balloon during an EVAR case reduces intraoperative waste, minimizing overall instrument cost per procedure. The potential to reduce operating room and catheter lab time may contribute to faster room turnover and more on-time procedural starts, according to Gore.

For more information: www.goremedical.com

Related Content

News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Technology | Balloon Catheter

March 21, 2018 — Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) ...

Home March 21, 2018
Home
News | Balloon Catheter

January 24, 2018 — Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product ...

Home January 24, 2018
Home
News | Balloon Catheter

May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports of ...

Home May 22, 2017
Home
Videos | Balloon Catheter

A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the ...

Home November 16, 2016
Home
Subscribe Now